Navigation Links
Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
Date:5/21/2008

LAWRENCEVILLE, N.J., May 21 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a marketing and distribution agreement with PharmaLink Asia Pacific Pte. Ltd. to enable Aton to expand distribution into several countries in Asia and Australia.

"This partnership marks an important milestone for Aton as we execute our mission to expand access to our medically essential portfolio of products," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "PharmaLink is uniquely qualified to help us expand our reach into the Asia Pacific region."

"Aton has a portfolio of unique products, and we are excited to partner with them to serve patients who rely on the availability of these medicines," stated Dr. George Eassey, VP of PharmaLink Asia Pacific. "We look forward to a long and successful partnership with Aton."

PharmaLink is a subsidiary of the INVIDA group and a leading provider of pharmaceutical and healthcare marketing and sales services in the Asia Pacific region. PharmaLink's strong presence, with subsidiaries across Asia Pacific and associates representing 13 countries within the region, as well as the company's in-depth understanding of these markets, enables PharmaLink to enhance the potential of clients' brands and products.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under-treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

About Invida Pharmaceutical Holdings Pte. Ltd.

Invida Pharmaceutical Holdings Pte. Ltd. is a specialty pharmaceutical company and the parent of PharmaLink, which is the leading pharmaceutical and healthcare commercialization services provider in Asia Pacific; and Inovail, an independently-managed, specialty pharmaceutical company focused on market-driven innovation in the areas of dermatology, complementary oncology and female healthcare. Headquartered in Singapore, Invida's focus is in the Asia Pacific region, where it has offices in 13 countries. Its shareholders include Temasek Holdings, Quintiles Transnational and the Zuellig Group. More information about Invida can be found at http://www.invida.com.


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2. Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
3. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
4. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
5. Pharmaxis Aridol Authorised for Sale in Germany
6. Takeda Pharmaceuticals Establishes $3 Million Endowment with AGA Foundation
7. China Pharma Holdings, Inc. Donates Medicine for Sichuan Earthquake Relief
8. MAP Pharmaceuticals to Present at the 2008 Citi Investment Research Global Healthcare Conference
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R)
11. Transdel Pharmaceuticals Closes $4 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. ... San Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, ... government officials from around the world to address key issues in device compliance, quality ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):